BioSpace News Archive

Policy

McKesson Applauds DOJ Policy Change on Opioid Quotas

Company previously called for revisions to production quota

July 12, 2018
·
2 min read
Business

ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2018 Operating Results

ImmunoGen, Inc., announced that Company will host a conference call at 8:00 a.m. ET on Friday, July 27, 2018 to discuss its second quarter operating results.

July 12, 2018
·
1 min read
Business

Arcus Biosciences Announces That Taiho Pharmaceutical Has Exercised Its Option to Develop and Commercialize AB928 in Its Territories

Arcus Biosciences, Inc. announced that Taiho Pharmaceutical Co., Ltd. exercised its option under the Option and License Agreement entered into in September 2017 (Taiho Agreement) to obtain an exclusive development and commercialization license to the Company’s adenosine receptor antagonist program

July 12, 2018
·
5 min read
Business

Professional Hockey Players Invest in Cannabis-Based Medical SolutionGAVIN Hockey Wealth Specialists Aligns With NY-Based CB1 Capital Management

GAVIN Hockey Wealth Specialists is teaming up with CB1 Capital Management, LLC. CB1 invests in the supply chain of cannabinoid-based wellness solutions, products and therapies that address a wide range of unmet medical conditions and use-cases.

July 12, 2018
·
2 min read
BioMidwest

Navidea Management to Host Moderated Q&A Webcast to Provide Corporate Update

Webcast will also focus on Proxy Updates

July 12, 2018
·
2 min read
Business

Advocare And GuideIT Enter Strategic IT Relationship

Advocare, LLC and GuideIT announced a strategic IT relationship focused on supporting a new Electronic Health Record implementation.

July 12, 2018
·
2 min read
Policy

Johnson & Johnson’s Official Statement in Response to Today’s Verdict in St. Louis Trial

Johnson & Johnson (NYSE: JNJ) issued the following statement regarding today’s verdict in the St. Louis court.

July 12, 2018
·
1 min read
Deals

Spero Therapeutics Announces Pricing of Securities Offering

Spero Therapeutics, Inc. announced the pricing of an underwritten public offering of 3,780,000 shares of its common stock and 2,220 shares of its non-voting Series A Convertible Preferred Stock.

July 12, 2018
·
3 min read
Deals

Myovant Sciences Ltd. Announces Pricing of $75.0 Million Public Offering of Common Shares

Myovant Sciences Ltd. announced the pricing of its underwritten public offering of 3,333,334 of its common shares at a price to the public of $22.50 per share.

July 12, 2018
·
3 min read
Business

Novartis to Drop Anti-Infectives Research Programs and Lay Off 140

The Novartis Institutes for BioMedical Research (NIBR) is ending its early-stage anti-infectives research programs located in Emeryville, California. As a result, the company expects to lay off about 140 employees.

July 12, 2018
·
2 min read
·
Mark Terry